15 research outputs found
Comparison of conventional and liquid-based cytology using The Paris System for Reporting Urinary Cytology
Background This retrospective study was conducted to compare the
conventional cytospin method and ThinPrep liquid-based urinary cytology
in diagnosing bladder cancer using The Paris System (TPS) of
classification. Methods We retrieved files for 2020, at the
Cytopathology Department of Laiko Hospital, of urinary cases diagnosed
according to TPS. Cytospin and ThinPrep slides were separately reviewed
and new diagnoses were rendered, then compared with the original
diagnosis and histology when available. Risk of high-grade malignancy
(ROHM) for each TPS category was assessed, along with accuracy
parameters of each method and their combination. Results The study
material comprised 100 cases of void urinary cytology classified as 20
high-grade urothelial carcinoma (HGUC = TPS5) cases, 20 of suspicion for
HGUC (SHGUC = TPS4), 25 of atypical urothelial cells (AUC = TPS3), and
35 of negative for HGUC (NHGUC = TPS2). A single inadequate (TPS1) case
and 4 of low-grade urothelial neoplasm (TPS6) were excluded as small in
number. The ROHM was 95% for HGUC, 55% for SHGUC, 28% for AUC and
5.7% for NHGUC. Agreement with the original diagnosis was 86% for
cytospin and 82% for ThinPrep. No significant differences were observed
among the two techniques or their combination regarding sensitivity and
specificity, with a mild advantage for cytospin. Interobserver
reproducibility and repeatability were high. Conclusion No significant
differences were found concerning sensitivity and specificity between
cytospin and ThinPrep when applying TPS criteria. TPS is a reliable
classification scheme for either conventional/cytospin or liquid-based
cytology, or their combination
Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer
OBJECTIVES To determine whether intermittent docetaxel might control
disease while limiting the toxicity and improving the quality-of-life
parameters in patients with advanced, castrate-resistant prostate
cancer. Intermittent docetaxel represents an appealing therapeutic
approach.
METHODS We reviewed the records of 35 patients with chemotherapy-naive
castrate-resistant prostate cancer who had received docetaxel 45 mg/m(2)
every 2 weeks, with oral prednisone 5 mg twice daily. Treatment was held
when the patients had reached a > 50% prostate-specific antigen
reduction from baseline that was confirmed by a second measurement 4
weeks later, in the absence of disease progression. Docetaxel was
resumed at a > 25% prostate-specific antigen increase from the nadir
level, also confirmed by a second measurement 4 weeks later, or in cases
of documented disease progression.
RESULTS Of the 35 patients, 18 (51.42%) had entered the first
chemotherapy-free interval (CFI) after a median of 6 infusions (range
2-12), 6 patients had entered a second CFI after a median of 4 months
(range 2-12), and 1 patient, a third CFI at the last follow-up point.
The median interval “off chemotherapy” was 4.5 months (range 1-16)
for the first CFI. Two patients discontinued docetaxel because of Grade
4 nonhematologic toxicity. The median interval to treatment failure was
8.1 months (95% confidence interval 5.1-12.2) for the entire cohort and
12.2 months (95% confidence interval 8.3-25+) for the patients who had
entered the first CFI.
CONCLUSIONS The results of our study have shown that intermittent
docetaxel is a clinically active and likely more tolerable and less
costly therapeutic strategy for patients with castrate-resistant
prostate cancer than continuous administration. Additional validation of
this approach is warranted. UROLOGY 77: 682-687, 2011. (C) 2011 Elsevier
Inc
Intermittent Docetaxel Chemotherapy in Patients With Castrate-resistant Prostate Cancer
OBJECTIVES To determine whether intermittent docetaxel might control
disease while limiting the toxicity and improving the quality-of-life
parameters in patients with advanced, castrate-resistant prostate
cancer. Intermittent docetaxel represents an appealing therapeutic
approach.
METHODS We reviewed the records of 35 patients with chemotherapy-naive
castrate-resistant prostate cancer who had received docetaxel 45 mg/m(2)
every 2 weeks, with oral prednisone 5 mg twice daily. Treatment was held
when the patients had reached a > 50% prostate-specific antigen
reduction from baseline that was confirmed by a second measurement 4
weeks later, in the absence of disease progression. Docetaxel was
resumed at a > 25% prostate-specific antigen increase from the nadir
level, also confirmed by a second measurement 4 weeks later, or in cases
of documented disease progression.
RESULTS Of the 35 patients, 18 (51.42%) had entered the first
chemotherapy-free interval (CFI) after a median of 6 infusions (range
2-12), 6 patients had entered a second CFI after a median of 4 months
(range 2-12), and 1 patient, a third CFI at the last follow-up point.
The median interval “off chemotherapy” was 4.5 months (range 1-16)
for the first CFI. Two patients discontinued docetaxel because of Grade
4 nonhematologic toxicity. The median interval to treatment failure was
8.1 months (95% confidence interval 5.1-12.2) for the entire cohort and
12.2 months (95% confidence interval 8.3-25+) for the patients who had
entered the first CFI.
CONCLUSIONS The results of our study have shown that intermittent
docetaxel is a clinically active and likely more tolerable and less
costly therapeutic strategy for patients with castrate-resistant
prostate cancer than continuous administration. Additional validation of
this approach is warranted. UROLOGY 77: 682-687, 2011. (C) 2011 Elsevier
Inc